Trial reportBritish journal of clinical pharmacology2026
Dose effect of buspirone combined with clozapine on cognitive function in patients with schizophrenia.
Trial report in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dose effect of buspirone combined with clozapine on cognitive function in patients with schizophrenia.British journal of clinical pharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to evaluate the augmentation effects of different doses of buspirone on psychiatric symptoms and cognitive function in patients with schizophrenia.
methodsA prospective study design was employed, enrolling 46 patients with schizophrenia treated at the Fourth People's Hospital of Wuhu. Patients were randomly assigned to three groups: a control group, experimental group 1 (5 mg of buspirone) or experimental group 2 (10 mg of buspirone). The control group received clozapine monotherapy, whereas the experimental groups received adjunctive buspirone at different doses alongside clozapine. The Positive and Negative Syndrome Scale (PANSS) and the Chinese version of the Repeatable Battery for the Assessment of Neuropsychological Status were used to assess psychiatric symptoms and cognitive function. A linear mixed-effects model was employed for statistical analysis.
resultsAfter 4 weeks of treatment, both experimental groups showed greater reductions in total PANSS scores than the control group (d = 0.68 and 0.82, respectively), with improvements in positive and negative symptoms being particularly pronounced in experimental group 2 (d = 0.68 and 0.85, respectively). By week 8, general symptoms had improved significantly in both experimental groups. < u > A significant group × time interaction was observed (partial η
conclusionsBuspirone is effective in alleviating psychiatric symptoms and cognitive deficits in patients with schizophrenia, thereby enhancing clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.